Spirituality

Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan

Carbonaro, T. M., Johnson, M. W., & Griffiths, R. R | Psychopharmacology | 5 June 2020

Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review

Heuschkel, K., & Kuypers, K. P. | Frontiers in Psychiatry | 31 March 2020

Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications.

O’Callaghan, C., Hubik, D. J., Dwyer, J., Williams, M., & Ross, M. | Journal of Music Therapy | 30 March 2020

Ayahuasca’s ‘afterglow’: improved mindfulness and cognitive flexibility in ayahuasca drinkers.

Murphy-Beiner, A., & Soar, K. | Psychopharmacology | 11 January 2020

Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.

Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., ... & Ross, S. | Journal of Psychopharmacology | 9 January 2020

Psychedelics in Western culture: unnecessary psychiatrisation of visionary experiences

Hanegraaff, W. J. | Tijdschrift Voor Psychiatrie | 01 Jan 2020

Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects

Smigielski, L., Scheidegger, M., Kometer, M., & Vollenweider, F. X. | NeuroImage | 1 August 2019

Replication and extension of a model predicting response to psilocybin

Russ, S. L., Carhart-Harris, R. L., Maruyama, G., & Elliott, M. S. | Psychopharmacology | 15 June 2019

Survey of subjective “God encounter experiences”: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.

Griffiths, R. R., Hurwitz, E. S., Davis, A. K., Johnson, M. W., & Jesse, R. | PloS one | 23 April 2019

Palliative Nursing and Sacred Medicine: A Holistic Stance on Entheogens, Healing, and Spiritual Care.

Rosa, W. E., Hope, S., & Matzo, M. | Journal of Holistic Nursing | 18 April 2018

Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder

Brown, T. K., Noller, G. E., & Denenberg, J. O. | Journal of psychoactive drugs | 9 April 2019

Neurochemical models of near-death experiences: A large-scalestudy based on the semantic similarity of written reports

Martial, C., Cassol, H., Charland-Verville, V., Pallavicini, C., Sanz, C., Zamberlan, F., & Tagliazucchi, E. | Consciousness and cognition | 20 January 2019

A Jamesian Response to Reductionism in the Neuropsychology of Religious Experience

Kime, K. G., & Snarey, J. R. | Archive for the Psychology of Religion | 13 December 2018

What Psilocybin Taught Me About Dying

Back, A. L. | Journal of palliative medicine | 9 November 2018

Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers.

Corkery, J. M. | Progress in brain research | 12 October 2018

DARK Classics in Chemical Neuroscience: Ibogaine.

Wasko, M. J., Witt-Enderby, P. A., & Surratt, C. K. | ACS chemical neuroscience | 9 October 2018

Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy

Hendricks, P. S. | International Review of Psychiatry | 27 September 2018

Psychedelics and music: neuroscience and therapeutic implications

Barrett, F. S., Preller, K. H., & Kaelen, M. | International Review of Psychiatry | 21 September 2018

A Gratuitous Grace: The Influence of Religious Set and Intent on the Psychedelic Experience

Neitzke-Spruill, L., & Glasser, C. | Journal of psychoactive drugs | 27 July 2018

The epidemiology of 5-methoxy- N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption

Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E. | Journal of Psychopharmacology | 30 April 2018

The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption